Read Full Article
The Japanese pharmaceutical company Takeda is buying Cambridge, Massachussets-based Ariad Pharmaceuticals for $24 a share. The deal is valued at about $5.2 billion and expected to close in February...
This is a very exciting time for Takeda as we will broaden our hematology portfolio and transform our global solid tumor franchise through the addition of two innovative targeted therapies.
The acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders.